# US 8,541,546 B2 · WDRPUH epitope peptides and vaccines containing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,546 B2
- Document ID: US8541546B2
- Status: Granted
- Kind: B2
- Application number: 13/132,891
- Filed: 2009-12-03
- Published: 2011-12-01
- Granted: 2013-09-24
- Earliest claimed: 2008-12-05
- Assignees: Oncotherapy Science, Inc.
- Applicants: Takuya Tsunoda; Ryuji Ohsawa; Sachiko Yoshimura; Tomohisa Watanabe
- Inventors: Takuya Tsunoda; Ryuji Ohsawa; Sachiko Yoshimura; Tomohisa Watanabe
- Web page: https://patentgrep.com/patent/US8541546B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 39/0011: {Cancer antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/47: from mammals
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

## Claims

### Claim 1

An isolated peptide of less than 15 amino acids selected from the group consisting of:
(a) an isolated peptide, which comprises the amino acid sequence as shown in SEQ ID NO: 2; and
(b) an isolated peptide, which comprises the amino acid sequence as shown in SEQ ID NO: 2 in which 1 or 2 amino acid(s) are substituted and/or added, wherein the added amino acid(s) are added to the N-terminus and/or the C-terminus.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide has one or both of the following characteristics:
(a) the second amino acid from the N-terminus is selected from the group consisting of phenylalanine, tyrosine, methionine and tryptophan; and
(b) the C-terminal amino acid is selected from the group consisting of phenylalanine, leucine, isoleucine, tryptophan and methionine.

### Claim 3 (depends on 1)

The isolated peptide of claim 1, which binds to an HLA antigen.

### Claim 4 (depends on 3)

The isolated peptide of claim 3, wherein the HLA antigen is HLA-A24.

### Claim 5 (depends on 1)

The isolated peptide of claim 1, which is a nonapeptide or a decapeptide.

### Claim 6 (depends on 1)

The isolated peptide of claim 1, which has CTL inducibility.